Search Result

Pathways Recommended:	Membrane Transporter/Ion Channel
Isoforms Recommended:	N-type calcium channel

Results for "

N-type calcium channel

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Calcium Channel (22) Sodium Channel (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (3) Inflammation/Immunology (3) Neurological Disease (20)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Targets Recommended: Calcium Channel CRAC Channel Scavenger Receptor Class B type I (SR-BI） CaSR Calmodulin PCSK9 Chloride Channel HCN Channel TRP Channel Sodium Channel Potassium Channel Piezo Channel

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P0062B

Ziconotide acetate SNX-111 acetate	Calcium Channel	Cardiovascular Disease Inflammation/Immunology Cancer
Ziconotide acetate (SNX-111 acetate), a peptide, is a potent and selective block of **N-type calcium channels** antagonist. Ziconotide acetate reduces synaptic transmission, and can be used for chronic pain research .

HY-147638

MONIRO-1	Calcium Channel	Neurological Disease
MONIRO-1 is a T-type and N-type **calcium channel blocker with IC₅₀ values of 34, 3.3, 1.7 and 7.2 µM against hCa_v2.2, hCa_v3.1, hCa_v3.2 and hCa_v3.3**, respectively .

HY-U00236

PD0176078	Calcium Channel	Cardiovascular Disease
PD0176078 is a newly found N-type **Calcium channel** blocker.

HY-14462

NP118809 39-1B4	Calcium Channel	Cardiovascular Disease
NP118809 is a potent **N-type calcium channel blocker, with an IC₅₀** of 0.11 μM; also less potently inhibits L-type calcium channel with an IC₅₀ of 12.2 μM.

HY-103318

PD173212 1 Publications Verification	Calcium Channel	Neurological Disease
PD173212 is a selective N-type voltage sensitive calcium channel (VSCC) blocker, with an IC₅₀ of 36 nM in IMR-32 assays.

HY-100310

N-type calcium channel blocker-1	Calcium Channel	Neurological Disease
N-type calcium channel blocker-1 is an orally active compound which shows high affinity to functionally block **N-type calcium channels with an IC₅₀** of 0.7 μM in the IMR32 assay.

HY-120751

TROX-1	Calcium Channel	Neurological Disease
TROX-1 is an N-type **calcium channel (CaV2.2) inhibitor with an IC₅₀** value of 0.11 μM. TROX-1 can be used in chronic pain research .

HY-P0062

Ziconotide SNX-111	Calcium Channel	Neurological Disease Inflammation/Immunology Cancer
Ziconotide (SNX-111), a peptide, is a potent and selective block of **N-type calcium channels** antagonist. Ziconotide reduces synaptic transmission, and can be used for chronic pain research .

HY-P0062A

Ziconotide TFA SNX-111 TFA	Calcium Channel	Neurological Disease Inflammation/Immunology Cancer
Ziconotide TFA (SNX-111 TFA), a peptide, is a potent and selective block of **N-type calcium channels** antagonist. Ziconotide TFA reduces synaptic transmission, and can be used for chronic pain research .

HY-P1078

Huwentoxin XVI	Calcium Channel	Neurological Disease
Huwentoxin XVI, an analgesic, is a highly reversible and selective mammalian **N-type calcium channel (IC₅₀** of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels .

HY-P1078A

Huwentoxin XVI TFA	Calcium Channel	Neurological Disease
Huwentoxin XVI TFA, an analgesic, is a highly reversible and selective mammalian **N-type calcium channel (IC₅₀** of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI TFA has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels .

HY-119373

Cav 2.2 blocker 1 1 Publications Verification	Calcium Channel	Neurological Disease
Cav 2.2 blocker 1 (compound 9) is a N-type calcium channel (Cav 2.2) blocker for the treatment of pain, with an IC₅₀ of 1 nM .

HY-P5179

Huwentoxin I HWTX-I	Calcium Channel Sodium Channel	Neurological Disease
Huwentoxin I (HWTX-I) is a peptide toxin that inhibits voltage-gated sodium channels and N-type **calcium channels*. Huwentoxin I inhibits sodium channels* in rat hippocampus and cockroach dorsal unpaired median (DUM) neurons with IC₅₀ values of 66.1 and 4.80 nM, respectively .

HY-118974

PD-151307	Calcium Channel	Neurological Disease Cancer
PD-151307 is an N-type **calcium channel antagonist with significant inhibitory effects in IMR-32 human neuroblastoma cells, exhibiting an IC₅₀** of 0.32 µM. PD-151307 can be used in research related to cancer therapy, anticonvulsants, and neuropathic pain .

HY-P2699

ω-Grammotoxin SIA GrTx; ω-GsTx SIA	Calcium Channel	Neurological Disease
ω-Grammotoxin SIA (GrTx) is P/Q and N-type voltage-gated **Calcium channels** inhibitor. ω-Grammotoxin SIA is also a protein toxin that can be obtained from spider venom. ω-Grammotoxin SIA has the potential to study neurological diseases as well as cardiovascular diseases .

HY-P1080

ω-Agatoxin IVA	Calcium Channel	Neurological Disease
ω-Agatoxin IVA is a potent, selective P/Q type Ca ²⁺ (Cav2.1) channel blocker with IC₅₀s of 2 nM and 90 nM for *P-type* and Q-type Ca ²⁺ channels, respectively. ω-Agatoxin IVA (IC₅₀, 30-225 nM) inhibits glutamate exocytosis and calcium influx elicited by high potassium. ω-Agatoxin IVA also blocks the high potassium-induced release of serotonin and norepinephrine. ω-Agatoxin IVA has no effect on L-type or N-type calcium channels .

HY-P1079

ω-Agatoxin TK	Calcium Channel	Neurological Disease
ω-Agatoxin TK, a peptidyl toxin of the venom of Agelenopsis aperta, is a potent and selective P/Q type Ca ²⁺ channel blocker. ω-Agatoxin TK inhibits the high K ⁺ depolarisation-induced rise in internal Ca ²⁺ in cerebral isolated nerve endings with an IC₅₀ of of 60 nM. ω-Agatoxin TK has no effect on L-type, N-type, or T-type calcium channels .

HY-P1080A

ω-Agatoxin IVA TFA	Calcium Channel	Neurological Disease
ω-Agatoxin IVA TFA is a potent, selective P/Q type Ca ²⁺ (Cav2.1) channel blocker with IC₅₀s of 2 nM and 90 nM for *P-type* and Q-type Ca ²⁺ channels, respectively. ω-Agatoxin IVA TFA (IC₅₀, 30-225 nM) inhibits glutamate exocytosis and calcium influx elicited by high potassium. ω-Agatoxin IVA TFA also blocks the high potassium-induced release of serotonin and norepinephrine. ω-Agatoxin IVA TFA has no effect on L-type or N-type calcium channels .

HY-103309

ML218 1 Publications Verification	Calcium Channel	Neurological Disease
ML218 is a potent, selective and orally active *T-type* Ca ²⁺ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC₅₀s of 310 nM and 270 nM for Cav3.2 and Cav3.3*, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type* calcium channels, K_ATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier .

HY-103309A

ML218 hydrochloride	Calcium Channel	Neurological Disease
ML218 hydrochloride is a potent, selective and orally active *T-type* Ca ²⁺ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC₅₀s of 310 nM and 270 nM for Cav3.2 and Cav3.3*, respectively. ML218 hydrochloride inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 hydrochloride has no significant inhibition of L- or N-type* calcium channels, K_ATP or hERG potassium channels. ML218 hydrochloride can penetrate the blood-brain barrier .

HY-W269511

NW-1689	Others	Neurological Disease
NW-1689 is a process-related impurity of safinamide mesilate (SAFM). SAFM is a drug used to treat Parkinson's disease (PD). It is a highly selective and reversible inhibitor of monoamine oxidase-B (MAO-B) and also blocks sodium channels and **N-type calcium channels**. These effects of SAFM help reduce the breakdown of dopamine and inhibit the release of glutamate. NW-1689 has a similar chemical structure to SAFM and has some similar pharmacological effects as SAFM, and can be used in Parkinson's disease research .

HY-103309S

ML218-d9	Calcium Channel	Neurological Disease
ML218-d₉ is the deuterium labeled ML218. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier[1].

HY-147639

Cav 2.2/3.2 blocker 1	Calcium Channel	Neurological Disease
Cav 2.2/3.2 blocker 1 (Compound 9e) is a neuronal calcium channel blocker with IC₅₀ values of 78 μM and 80 μM against Ca_v2.2 and Ca_v3.2, respectively. Cav 2.2/3.2 blocker 1 can penetrate the CNS .

Cat. No.	Product Name	Target	Research Area

HY-P0062B

Ziconotide acetate SNX-111 acetate	Calcium Channel	Cardiovascular Disease Inflammation/Immunology Cancer
Ziconotide acetate (SNX-111 acetate), a peptide, is a potent and selective block of **N-type calcium channels** antagonist. Ziconotide acetate reduces synaptic transmission, and can be used for chronic pain research .

HY-P1080A

ω-Agatoxin IVA TFA	Calcium Channel	Neurological Disease
ω-Agatoxin IVA TFA is a potent, selective P/Q type Ca ²⁺ (Cav2.1) channel blocker with IC₅₀s of 2 nM and 90 nM for *P-type* and Q-type Ca ²⁺ channels, respectively. ω-Agatoxin IVA TFA (IC₅₀, 30-225 nM) inhibits glutamate exocytosis and calcium influx elicited by high potassium. ω-Agatoxin IVA TFA also blocks the high potassium-induced release of serotonin and norepinephrine. ω-Agatoxin IVA TFA has no effect on L-type or N-type calcium channels .

HY-P0062

Ziconotide SNX-111	Calcium Channel	Neurological Disease Inflammation/Immunology Cancer
Ziconotide (SNX-111), a peptide, is a potent and selective block of **N-type calcium channels** antagonist. Ziconotide reduces synaptic transmission, and can be used for chronic pain research .

HY-P0062A

Ziconotide TFA SNX-111 TFA	Calcium Channel	Neurological Disease Inflammation/Immunology Cancer
Ziconotide TFA (SNX-111 TFA), a peptide, is a potent and selective block of **N-type calcium channels** antagonist. Ziconotide TFA reduces synaptic transmission, and can be used for chronic pain research .

HY-P1078

Huwentoxin XVI	Calcium Channel	Neurological Disease
Huwentoxin XVI, an analgesic, is a highly reversible and selective mammalian **N-type calcium channel (IC₅₀** of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels .

HY-P1078A

Huwentoxin XVI TFA	Calcium Channel	Neurological Disease
Huwentoxin XVI TFA, an analgesic, is a highly reversible and selective mammalian **N-type calcium channel (IC₅₀** of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI TFA has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels .

HY-P5179

Huwentoxin I HWTX-I	Calcium Channel Sodium Channel	Neurological Disease
Huwentoxin I (HWTX-I) is a peptide toxin that inhibits voltage-gated sodium channels and N-type **calcium channels*. Huwentoxin I inhibits sodium channels* in rat hippocampus and cockroach dorsal unpaired median (DUM) neurons with IC₅₀ values of 66.1 and 4.80 nM, respectively .

HY-P2699

ω-Grammotoxin SIA GrTx; ω-GsTx SIA	Calcium Channel	Neurological Disease
ω-Grammotoxin SIA (GrTx) is P/Q and N-type voltage-gated **Calcium channels** inhibitor. ω-Grammotoxin SIA is also a protein toxin that can be obtained from spider venom. ω-Grammotoxin SIA has the potential to study neurological diseases as well as cardiovascular diseases .

HY-P1080

ω-Agatoxin IVA	Calcium Channel	Neurological Disease
ω-Agatoxin IVA is a potent, selective P/Q type Ca ²⁺ (Cav2.1) channel blocker with IC₅₀s of 2 nM and 90 nM for *P-type* and Q-type Ca ²⁺ channels, respectively. ω-Agatoxin IVA (IC₅₀, 30-225 nM) inhibits glutamate exocytosis and calcium influx elicited by high potassium. ω-Agatoxin IVA also blocks the high potassium-induced release of serotonin and norepinephrine. ω-Agatoxin IVA has no effect on L-type or N-type calcium channels .

HY-P1079

ω-Agatoxin TK	Calcium Channel	Neurological Disease
ω-Agatoxin TK, a peptidyl toxin of the venom of Agelenopsis aperta, is a potent and selective P/Q type Ca ²⁺ channel blocker. ω-Agatoxin TK inhibits the high K ⁺ depolarisation-induced rise in internal Ca ²⁺ in cerebral isolated nerve endings with an IC₅₀ of of 60 nM. ω-Agatoxin TK has no effect on L-type, N-type, or T-type calcium channels .

Cat. No.	Product Name	Chemical Structure

HY-103309S

ML218-d9
ML218-d₉ is the deuterium labeled ML218. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier[1].

ML218-d9

ML218-d₉ is the deuterium labeled ML218. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: